Hohenstein Ernstthal

Researchers are evaluating the long-term effects of Dupilumab treatment on patients with Chronic Obstructive Pulmonary Disease (COPD) in a real-world setting over 24 months. The study focuses on changes in health-related quality of life, patient characteristics, effectiveness, and safety of Dupilumab for those whose COPD remains uncontrolled despite standard therapies and who have elevated blood eosinophils. This is a non-interventional study where patients receive Dupilumab as prescribed by their doctors according to approved guidelines, without any treatment administered by the study itself. Dupilumab treatment initiation happens independently from study recruitment, and patient data is collected during routine clinical care. Participants will be involved for up to 12 months with assessments including monitoring changes in the COPD Assessment Test (CAT) score from baseline. Data is gathered through clinical evaluations and patient-reported outcomes. Safety and effectiveness are observed through regular documentation of clinical health and patient experiences during their ongoing treatment.